A Phase 1 interventional study of Evorpacept (ALX148) and Pembrolizumab in Metastatic Cancer, Solid Tumor and Advanced Cancer, sponsored by ALX Oncology Inc.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-01.
Sponsored by ALX Oncology Inc. · Phase 1, Interventional, and Treatment
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of evorpacept (ALX148). The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation portion followed by a dose expansion portion. Approximately 184 adult patients are expected to be enrolled in the study.
Exclusion Criteria:
The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.
Drug: Evorpacept (ALX148)
The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
Drug: Evorpacept (ALX148) · Drug: Pembrolizumab
The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
Drug: Evorpacept (ALX148) · Drug: Trastuzumab
The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.
Drug: Evorpacept (ALX148) · Drug: Rituximab
The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
Drug: Evorpacept (ALX148) · Drug: Pembrolizumab · Drug: 5-FU + Cisplatin
The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
Drug: Evorpacept (ALX148) · Drug: Trastuzumab · Drug: Ramucirumab + Paclitaxel
Evorpacept (ALX148)
Keytruda
Herceptin
Rituxan
Standard of care chemotherapy
Standard of care chemotherapy
Dose-limiting toxicities (Number of participants with a DLT)
Number of participants with a DLT
Time frame: Up to 28 days
Plan to share: No
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ALX Oncology Inc.